Metastatic Uveal Melanoma - Pipeline Insight, 2025

DelveInsight’s, “Metastatic Uveal Melanoma - Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Metastatic Uveal Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic Uveal Melanoma Understanding

Metastatic Uveal Melanoma: Overview

Uveal melanoma represents ∼85% of all ocular melanomas and up to 50% of patients develop metastatic disease. Metastases are most frequently localized to the liver and, as few patients are candidates for potentially curative surgery, this is associated with a poor prognosis. There is currently little published evidence for the optimal management and treatment of metastatic uveal melanoma and the lack of effective therapies in this setting has led to the widespread use of systemic treatments for patients with cutaneous melanoma. Uveal and cutaneous melanomas are intrinsically different diseases and so dedicated management strategies and therapies for uveal melanoma are much needed.

""Metastatic Uveal Melanoma - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Uveal Melanoma pipeline landscape is provided which includes the disease overview and Metastatic Uveal Melanoma treatment guidelines. The assessment part of the report embraces, in depth Metastatic Uveal Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Uveal Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Uveal Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Uveal Melanoma.

Metastatic Uveal Melanoma Emerging Drugs Chapters

This segment of the Metastatic Uveal Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Uveal Melanoma Emerging Drugs

• Nivolumab: Bristol-Myers Squibb

Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. Opdivo is formulated as solution and concentrate solution for intravenous and subcutaneous route of administration. Nivolumab is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Opdivo is indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Opdivo in combination with ipilimumab, is indicated for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma. The drug is currently in phase II stage of clinical trial evaluation for the treatment of Metastatic Uveal Melanoma.

• Pembrolizumab: Merck & Co

Pembrolizumab (Keytruda) is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Pembrolizumab (Keytruda) is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 1,600 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers. The drug is currently in phase II stage of clinical trial evaluation for the treatment of Metastatic Uveal Melanoma.

Further product details are provided in the report……..

Metastatic Uveal Melanoma: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Uveal Melanoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Metastatic Uveal Melanoma

There are approx. 15+ key companies which are developing the therapies for Metastatic Uveal Melanoma. The companies which have their Metastatic Uveal Melanoma drug candidates in the most advanced stage, i.e. phase II include, Bristol-Myers Squibb.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Metastatic Uveal Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Uveal Melanoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic Uveal Melanoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Uveal Melanoma drugs.

Metastatic Uveal Melanoma Report Insights

• Metastatic Uveal Melanoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic Uveal Melanoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic Uveal Melanoma drugs?
• How many Metastatic Uveal Melanoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Uveal Melanoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Uveal Melanoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic Uveal Melanoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Bristol-Myers Squibb
• Merck & Co
• Verastem Oncology
• AstraZeneca
• IDEAYA Biosciences
• BioMed Valley Discoveries
• Miltenyi Biomedicine GmbH
• Vanquish Oncology
• Hoffmann-La Roche
• Linnaeus Therapeutics

Key Products

• Nivolumab
• Pembrolizumab
• Defactinib Hydrochloride
• IDE196
• BVD-523
• Ipilimumab
• Autologous Tumor Infiltrating Lymphocytes
• PAC-1
• RO7293583
• LNS8801